---
title: "浙江同源康醫藥股份有限公司 (02410.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02410.HK.md"
symbol: "02410.HK"
name: "浙江同源康醫藥股份有限公司"
industry: "生物技術"
---

# 浙江同源康醫藥股份有限公司 (02410.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 港股市場 |
| Website | [www.tykmedicines.com](https://www.tykmedicines.com) |

## Company Profile

浙江同源康醫藥股份有限公司是一家致力於開發及商業化醫藥產品的中國公司。該公司專注於小分子藥物開發,其主要產品包括TY-9591、TY-302和TY-2136。TY-9591是一種第叁代EGFR-TKI,對EGFR突變具有抗腫瘤作用。TY-302是一種為治療乳腺癌及前列腺癌等晚期實體瘤而開發的強效、選擇性口服CDK4/6抑製劑。TY-2136b為自主研發、口服ROS1/NTRK抑製劑,用於治療實體瘤。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-28T04:30:13.000Z

**Overall: C (0.60)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 26 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 34.45% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 12.24 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.79B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 116033.99 |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 81.23% | A |
| Profit Margin | -261756.07% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | D |
| Net Profit YoY | 34.45% | B |
| Total Assets YoY | 52.88% | A |
| Net Assets YoY | 135.03% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.04% | D |
| OCF YoY | 0.00% | D |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 54.87% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 浙江同源康醫藥股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "81.23%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-261756.07%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "34.45%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "52.88%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "135.03%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.04%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "54.87%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百濟神州 (HK.6160) | B | A | B | C | A | B |
| 02 | 信達生物 (HK.1801) | B | A | C | B | A | B |
| 03 | 三生制藥 (HK.1530) | A | B | C | A | C | B |
| 04 | 百奧賽圖-B (HK.2315) | A | A | C | D | B | B |
| 05 | 和鉑醫藥-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -15.59 | 41/70 | - | - | - |
| PB | 12.24 | 46/70 | 16.62 | 14.22 | 12.60 |
| PS (TTM) | 40814.70 | 58/70 | 71088.83 | 51245.12 | 42531.51 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-29T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.60 |
| Highest Target | 23.94 |
| Lowest Target | 23.94 |

## References

- [Company Overview](https://longbridge.com/en/quote/02410.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02410.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02410.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.